Vetoquinol SA is an international veterinary pharmaceutical company that develops, manufactures, and markets medicines and non-medicinal products for companion animals and livestock. Founded in 1933, the company focuses on a core portfolio of 'Essentiels' products, which include antiparasitics, antibiotics, and nutraceuticals for dogs, cats, cattle, and pigs. The group serves veterinarians, pet owners, and farmers across Europe, the United States, and the Asia-Pacific region, operating through direct subsidiaries and distributors. Vetoquinol operates manufacturing sites in France, Poland, Brazil, and Canada, and acquired Bioniche Animal Health in 2014 to expand its footprint in Australia. The company provides digital tools and training services to support veterinary practices, maintaining a business model centered on long-term partnerships with veterinary professionals.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - Specialty & Generic Homepage vetoquinol.com
Sector Healthcare IR page vetoquinol.com/en/investors
Tags
veterinary pharmaceuticals, companion animal health, livestock health, antiparasitics, nutraceuticals, animal diagnostics, veterinary services, Bioniche Animal Health
Press page vetoquinol.com/en/news

Metrics

Valuation  
Market cap € 826.147M
Market cap (USD) $ 919.253M
P/E 14.40
PEG 2.35
P/BV 1.40
P/S 1.53
P/OCF 11.46
P/FCF 15.01
Dividend yield —
Turnover / mcap —
Returns  
ROE 9.8%
ROI 9.7%
ROIC 9.5%
Profit margin 10.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 6.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 0.03%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 525.686M 539.196M 529.271M 539.779M 521.272M 427.467M 395.99M 367.941M 352.173M 350.354M 342.612M — — — — —
Net profit 57.36M 58.685M 55.56M 47.995M 62.861M 19.221M 28.247M 36.226M 34.838M 27.83M 24.16M — — — — —
Free cash flow 55.054M 71.281M 74.495M 45.884M 75.895M 81.893M — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 86.5 75 101.6 89.4 135 100 — — — — — — — — — —
Price performance 12m 0.15 -0.26 0.14 -0.34 0.35 — — — — — — — — — — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) 88.6M 87.2M 85.4M 99.2M 94.8M 99M
↳ YoY growth -1.6% -2.1% +16.2% -4.4% +4.4%
↳ 5y CAGR +2.2%
Borrowings, current (EUR) 112M 3.92M 3.3M 2.99M 4.39M 1.64M
Borrowings, non-current (EUR) 176,000 187,000 179,000 172,000 178,000 158,000
Lease liabilities (EUR) 12.4M 11.3M 13.9M 14.5M 16.6M 13.5M
Cash and deposits (EUR) 129M 69M 93.7M 147M 206M 221M
Intangible assets (EUR) 175M 179M 169M 154M 142M 130M
Right-of-use assets (EUR) 12.2M 11M 13.7M 14M 16M 12.9M
Net debt (borrowings + leases - cash) (EUR) -4.59M -53.6M -76.3M -130M -185M -206M
Cash flow detail
Operating cash flow (EUR) 92.2M 89.7M 62.9M 89.4M 85.8M 72.1M
Purchases of property, plant and equipment (EUR) -10.3M -13.8M -17M -14.9M -14.5M -17M
Purchases of intangible assets (EUR) -135M -18.6M -5.53M -4.11M -3.13M -3.71M
Dividends paid (cash effect) (EUR) -4.49M -5.91M -9.47M -9.47M -10.1M -10.4M
Interest paid (cash effect) (EUR) -601,000 -594,000 -737,000 -477,000 -481,000 -661,000
Income taxes paid (cash effect) (EUR) -12.5M -26.2M -31.9M -21.9M -21.8M -26.8M
Share-based compensation (EUR) 78,000 129,000 51,000 0.00 0.00 0.00
Free cash flow (OCF - PPE - intangibles) (EUR) -53.2M 57.3M 40.4M 70.4M 68.1M 51.3M
Income detail
Total comprehensive income (EUR) -9.41M 75.2M 52.9M 51.8M 62M 38.8M
Comprehensive income to owners (EUR) -9.42M 75.2M 52.9M 51.8M 62M 38.9M
Reported Apr 22, 2022 Apr 22, 2022 Apr 13, 2023 Apr 24, 2024 Apr 24, 2025 Apr 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Inside Information / Other news releases Bull 5 Bear 0 Clinical/regulatory

Prompts

Vetoquinol SA (ticker VETO), listed in France.

ETFs Holding Vetoquinol SA

ETF Weight in ETF Shares Market value As of
DFIS 0.01% 6,956 $ 681.259K Nov 12, 2026
DXIV 0.01% 235 $ 23.016K Nov 12, 2026
DFIC 0.00% 4,964 $ 486.166K Nov 12, 2026
DFSI 0.00% 305 $ 29.871K Nov 12, 2026
DFAX 0.00% 2,820 $ 276.186K Nov 12, 2026
DFAI 0.00% 1,293 $ 126.634K Nov 12, 2026